Prof Jean-François Baurain, medical oncologist at Cliniques universitaires Saint-Luc, Brussels sheds his light on the interim results of the phase 2 trial DESTINY-PanTumor-02, a tumor-agnostic study including a range of HER2-expressing solid tumors including cervical, endometrial and ovarian cancer.
With the educational support of:
